1. Home
  2. PCM vs CGTX Comparison

PCM vs CGTX Comparison

Compare PCM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCM Fund Inc.

PCM

PCM Fund Inc.

N/A

Current Price

$5.02

Market Cap

66.8M

Sector

Finance

ML Signal

N/A

CGTX

Cognition Therapeutics Inc.

N/A

Current Price

$0.89

Market Cap

79.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCM
CGTX
Founded
1993
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.8M
79.6M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
PCM
CGTX
Price
$5.02
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
88.9K
★ 368.0K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 11.68%
N/A
EPS Growth
N/A
★ 62.79
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.85
$0.55
52 Week High
$6.76
$2.05

Technical Indicators

Market Signals
Indicator
PCM
CGTX
Relative Strength Index (RSI) 30.19 49.14
Support Level $4.95 $0.95
Resistance Level $5.83 $1.18
Average True Range (ATR) 0.08 0.05
MACD 0.01 -0.00
Stochastic Oscillator 40.38 42.25

Price Performance

Historical Comparison
PCM
CGTX

About PCM PCM Fund Inc.

Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: